RESULTS

Table 1: Healthy Subject Baseline Characteristics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>AB-506 (n=10)</th>
<th>Cohort A (n=7)</th>
<th>Cohort C (n=10)</th>
<th>Pooled PBO (n=4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>41.7 (9.5)</td>
<td>41.3 (12.4)</td>
<td>40.8 (9.3)</td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>23.4 (3.5)</td>
<td>25.5 (5.6)</td>
<td>25.8 (2.4)</td>
<td></td>
</tr>
<tr>
<td>HBV DNA</td>
<td>&lt;LLOQ</td>
<td>&lt;LLOQ</td>
<td>&lt;LLOQ</td>
<td>&lt;LLOQ</td>
</tr>
</tbody>
</table>

Table 2: CHB Subject Baseline Characteristics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>AB-506 (n=10)</th>
<th>Cohort A (n=7)</th>
<th>Cohort C (n=10)</th>
<th>Pooled PBO (n=4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>26.2 (6.7)</td>
<td>27.5 (6.5)</td>
<td>24.8 (4.3)</td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>18.3 (5.4)</td>
<td>20.6 (5.0)</td>
<td>18.9 (5.9)</td>
<td></td>
</tr>
<tr>
<td>HBV DNA</td>
<td>4.23 (0.66)</td>
<td>3.62 (0.56)</td>
<td>3.52 (0.60)</td>
<td></td>
</tr>
</tbody>
</table>

METHODS

Figure 1: AB-506-001 Study Design

Figure 2: Mean (SD) Log10 Change from Baseline

Figure 3: Individual HBV DNA Change from Baseline

Figure 4: Grade 4 ALT vs HBV DNA to FU Day 28

Figure 5: ALT Value and HBV Viral Markers vs Time Subject 7002-001

Figure 6: AB-506 AUC and Cmax vs ALT Elevation

Figure 7: IP-10 and ALT Levels vs Time

Figure 8: T cell activation markers, HBsAg and ALT Levels over Time - Subject 7002-001

Figure 9: AB-506-003 Study Design

Figure 10: Grade 4 ALT Abnormalities AB-506-003

CONCLUSIONS

AB-506 demonstrated potent inhibition of HBV replication with mean declines in HBV DNA and HBsAg of 3.2 and 1.6 Log10, respectively.

Safety Findings:

- ALT elevations were noted in a subset of CHB subjects after the 14-day dosing period resulting in 3 (27%) do not appear dose related.
- Grade 4 elevations only occurred in subjects of East Asian ancestry.

Cytokine Profiling in Serum for Grade 4 ALTs:

- Serine IP-10 levels increased concordantly with ALT elevations.
- No other CHB subjects had these simultaneous increases in IP-10 and ALT.

CD8+ T cell activation markers, HBsAg and ALT levels over time were noted.

REFERENCES

AB-506-003 Demographics:

- Cohort A (European) contained 4 (57%) males and 3 (43%) females, BMI and baseline ALT were 27.1 (5.7), 27.4 (4.5) and 11.4 (7.0), respectively.
- Cohort B (Asian) contained 4 (57%) males and 3 (43%) females, BMI and baseline ALT were 27.1 (5.7), 27.4 (4.5) and 11.4 (7.0), respectively.

AB-506-003 Primary Objective:

- To evaluate the safety and tolerability of AB-506 following oral administration of multiple daily doses for 28 days in HB.

AB-506-003 Study Design:

- Cohort A (European) contained 4 (57%) males and 3 (43%) females, BMI and baseline ALT were 27.1 (5.7), 27.4 (4.5) and 11.4 (7.0), respectively.
- Cohort B (Asian) contained 4 (57%) males and 3 (43%) females, BMI and baseline ALT were 27.1 (5.7), 27.4 (4.5) and 11.4 (7.0), respectively.

AB-506-003 Participants:

- Cohort A (European) contained 4 (57%) males and 3 (43%) females, BMI and baseline ALT were 27.1 (5.7), 27.4 (4.5) and 11.4 (7.0), respectively.
- Cohort B (Asian) contained 4 (57%) males and 3 (43%) females, BMI and baseline ALT were 27.1 (5.7), 27.4 (4.5) and 11.4 (7.0), respectively.

AB-506-003 Adverse Events:

- Most AEs were Grade 1/2 and assessed as unrelated.
- No other clinically significant abnormalities were noted.
- No serious AEs were reported.

AB-506-003 Safety Summary:

- ALT elevations rapidly resolved post-discontinuation of AB-506.

AB-506-003 Non-Hepatitis A, B, C: ARUBUS BIOPHARMA, INC., 701 Veterans Circle, Warminster PA, 18974, USA

AB-506-003 Related Organizations:

- ARUBUS BIOPHARMA, INC., 701 Veterans Circle, Warminster PA, 18974, USA

AB-506-003 Acknowledgments:

- We also thank Christian Schwabe, MD (Auckland Clinical Studies, Ltd), Novotech Pty Limited (Auckland), University of Auckland, Auckland City Hospital, Auckland, New Zealand, for his contributions to the study.

AB-506-003 Exclusion Criteria:

- Most AEs were Grade 1/2 and assessed as unrelated.
- No other clinically significant abnormalities were noted.
- No serious AEs were reported.

AB-506-003 Conclusions:

- ALT elevations rapidly resolved post-discontinuation of AB-506.

AB-506-003 Summary:

- ALT elevations rapidly resolved post-discontinuation of AB-506.

AB-506-003 Further Study:

- Further development of AB-506 has been discontinued.